NPPA and familial dilated cardiomyopathy: Herein, we present and discuss pre-clinical and clinical evidence supporting the targeted restoration of biological activity of the corin-ANP axis as a valuable anti-fibrotic therapeutic strategy in DCM-HFrEF.